195 related articles for article (PubMed ID: 37905641)
21. Voriconazole-induced QT interval prolongation and torsades de pointes.
Aypar E; Kendirli T; Tutar E; Çiftçi E; Ince E; Ileri T; Atalay S
Pediatr Int; 2011 Oct; 53(5):761-763. PubMed ID: 21955009
[No Abstract] [Full Text] [Related]
22. Antimicrobial-associated QT interval prolongation: pointes of interest.
Owens RC; Nolin TD
Clin Infect Dis; 2006 Dec; 43(12):1603-11. PubMed ID: 17109296
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
[TBL] [Abstract][Full Text] [Related]
24. Torsade de pointes induced by systemic antifungal agents: lessons from a retrospective analysis of published case reports.
Justo D; Zeltser D
Mycoses; 2006 Nov; 49(6):463-70. PubMed ID: 17022762
[TBL] [Abstract][Full Text] [Related]
25. Cholinesterase inhibitors-associated torsade de pointes/QT prolongation: a real-world pharmacovigilance study.
Zhang N; Gan L; Xiang G; Xu J; Jiang T; Li Y; Wu Y; Ni R; Liu Y
Front Pharmacol; 2023; 14():1343650. PubMed ID: 38273821
[No Abstract] [Full Text] [Related]
26. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.
Weeke PE; Kellemann JS; Jespersen CB; Theilade J; Kanters JK; Hansen MS; Christiansen M; Marstrand P; Gislason GH; Torp-Pedersen C; Bundgaard H; Jensen HK; Tfelt-Hansen J
Eur Heart J; 2019 Oct; 40(37):3110-3117. PubMed ID: 31079148
[TBL] [Abstract][Full Text] [Related]
27. Fluconazole-induced torsade de pointes.
Tholakanahalli VN; Potti A; Hanley JF; Merliss AD
Ann Pharmacother; 2001 Apr; 35(4):432-4. PubMed ID: 11302406
[TBL] [Abstract][Full Text] [Related]
28. Relationship of clinical adverse event reports to models of arrhythmia risk.
Ether N; Leishman D; Bailie M; Lauver A
J Pharmacol Toxicol Methods; 2019; 100():106622. PubMed ID: 31398384
[TBL] [Abstract][Full Text] [Related]
29. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
[TBL] [Abstract][Full Text] [Related]
30. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
Schwartz PJ; Woosley RL
J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690
[TBL] [Abstract][Full Text] [Related]
31. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
33. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
34. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
35. Effect of atropine on QT prolongation and torsade de pointes induced by intracoronary acetylcholine in the long QT syndrome.
Furushima H; Niwano S; Chinushi M; Yamaura M; Taneda K; Washizuka T; Aizawa Y
Am J Cardiol; 1999 Mar; 83(5):714-8. PubMed ID: 10080424
[TBL] [Abstract][Full Text] [Related]
36. Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients.
Zeuli JD; Wilson JW; Estes LL
Antimicrob Agents Chemother; 2013 Mar; 57(3):1121-7. PubMed ID: 23229485
[TBL] [Abstract][Full Text] [Related]
37. Development of torsade de pointes caused by exacerbation of QT prolongation during clipping of cerebral artery aneurysm in a patient with subarachnoid haemorrhage.
Takenaka I; Aoyama K; Iwagaki T; Ishimura H; Kadoya T
Br J Anaesth; 2006 Oct; 97(4):533-5. PubMed ID: 16849385
[TBL] [Abstract][Full Text] [Related]
38. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
40. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
